Purple Biotech (NASDAQ:PPBT) Stock Price Crosses Above 50-Day Moving Average – Here’s What Happened

Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) crossed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $1.41 and traded as high as $1.49. Purple Biotech shares last traded at $1.49, with a volume of 20,258 shares trading hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Purple Biotech from a “sell (e+)” rating to a “sell (e)” rating in a report on Thursday, October 29th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $30.00.

Purple Biotech Trading Down 2.1%

The stock has a market capitalization of $1.42 million, a P/E ratio of -0.07 and a beta of 0.77. The company has a 50-day moving average price of $1.39 and a 200 day moving average price of $2.79.

Purple Biotech Company Profile

Purple Biotech Ltd. (NASDAQ:PPBT) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research programs are designed to address mechanisms that contribute to tumor growth, immune evasion and resistance to existing treatments. Purple Biotech’s pipeline has included CM24, a humanized monoclonal antibody targeting CEACAM1, an immune checkpoint involved in tumor-immune interactions. The company has evaluated CM24 in combination with other cancer therapies, including immune checkpoint inhibitors, for advanced solid tumors such as metastatic pancreatic cancer.